Industry
PamDx Secures €13 Million Series A Funding to Advance Deployment of Diagnostic Blood Tests for Cancer Patients Treated with Immunotherapy
Organon to be acquired by Sun Pharma, Strengthening its Global Women’s Health and Biosimilars Position
Sun Pharmaceutical Industries Limited has announced a definitive agreement to acquire Organon & Co. in an all-cash transaction valued at approximately $11.75 billion, marking one of the largest overseas acquisitions by an Indian pharmaceutical company to date. The transaction, which has been approved by the boards of both companies, is expected to close in early 2027, pending regulatory approvals and shareholder consent.
Organon, originally a Dutch company, but for many years a part of MSD (Merck & Co in the USA and Canada), has built a strong global presence with a portfolio of more than 70 products spanning women’s health, biosimilars, and established medicines. The company operates in over 140 countries and maintains six manufacturing facilities, including significant operations in Europe. Its Dutch roots remain visible, with major sites in Oss and offices in Amsterdam, employing thousands across the Netherlands and Belgium.
Approximately 10,000 people work for Organon globally, with around 2,500 employees based in the Netherlands and Belgium. The acquisition is therefore likely to draw close attention in the Dutch and Belgium life sciences ecosystem, particularly given Organon’s historical significance as a nearly century-old company that helped pioneer products for women's health.
Strategically, the acquisition aligns with Sun Pharma’s ambition to expand its innovative medicines portfolio while reinforcing its position in established brands and branded generics. The combined entity is expected to generate approximately $12.4 billion in revenue, placing it among the top 25 pharmaceutical companies worldwide.
Sun Pharma highlighted that the deal will significantly strengthen its footprint in women’s health, positioning the combined company among the top three globally in this segment. Organon’s portfolio includes treatments for contraception, menopause, and breast cancer—areas that Sun Pharma sees as key growth drivers. Access to these therapies is a major motivator behind the acquisition, alongside opportunities to expand into large markets such as China.
In addition, the transaction will enable Sun Pharma to enter the biosimilars space as a top-10 global player, leveraging Organon’s existing capabilities. The company also expects synergies through expanded market access, product launches, and operational efficiencies.
For the Dutch life sciences sector, the acquisition underscores continued global consolidation and highlights the enduring international relevance of Organon’s legacy. If completed, the deal will not only reshape Sun Pharma’s global standing but also mark a new chapter for one of the Netherlands’ most historically significant pharmaceutical companies.
